Therapeutics 2018

3 papers
Therapeutics 2018 featured research focused on clinical pharmacology, drug safety, and retrospective outcome analyses. One area of inquiry involved the prevalence and implications of off-label drug prescriptions within intensive care units, specifically highlighting clinical experiences in China. Other research directions included evidence-based evaluations of cardiovascular treatments, such as the perioperative use of recombinant human brain natriuretic peptide (rhBNP), through systematic reviews and meta-analyses. The year’s contributions also included clinical investigations into oncology, specifically regarding the management and literature review of small bowel gastrointestinal stromal tumors. Prolific contributors during this period included researchers such as Hongyu Yang, Jing Miao, and Qingwei Zhao. The collective work from 2018 emphasized the intersection of clinical practice and therapeutic efficacy across diverse medical specialties, including critical care, cardiology, and oncology. These studies reflect a focus on evaluating existing treatment protocols and drug safety profiles within specific clinical settings.

Papers

Title
Off-label prescriptions in intensive care unit: the Chinese experience
Safety and efficacy of the perioperative administration of recombinant human brain natriuretic peptide (rhBNP): a systematic review and meta-analysis
Small bowel gastrointestinal stromal tumor: a retrospective study of 32 cases at a single center and review of the literature